- Home
- QDEL vs QURE Comparison
QDEL vs QURE Comparison
Compare QDEL & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QDEL | QURE |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | QDEL | QURE |
|---|---|---|
| Price | $28.38 | $23.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $40.00 | ★ $56.25 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 02-11-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | $15,751,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.28 | $142.93 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.50 | $7.76 |
| 52 Week High | $43.92 | $71.50 |
Technical Indicators
Market Signals| Indicator | QDEL | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 48.24 |
| Support Level | $27.75 | $24.37 |
| Resistance Level | $30.50 | $26.97 |
| Average True Range (ATR) | 1.50 | 2.08 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 56.50 | 27.03 |
Price Performance
Historical ComparisonAbout QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.